Transplant center directory

In collaboration with Robert Wood Johnson University Hospital, a RWJBarnabas Health facility, the Blood and Marrow Transplant and Cellular Therapies Program at Rutgers Cancer Institute of New Jersey performs autologous, allogeneic, matched, mismatched, haploidentical and cord blood transplants and immune effector cell therapy. Ours is the only such program in New Jersey offered at an NCI-designated Comprehensive Cancer Center.

This center has been performing allogeneic transplants since 2002 and has been an NMDP/Be The Match transplant center since July 2005.

This center's actual 1-year survival results are similar to the expected rate for this center.

The survival information we have for this center includes ONLY:

1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2019, 2020, 2021, and
2. Who had their transplant at a U.S. transplant center, and
3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 107 patients.

The actual 1-year survival of these patients is 75.2%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 67.4% and 83.2%.

For help with understanding these statistics, please see Understanding Transplant Outcomes.

For overall survival for all patients transplanted with a specific disease, please see U.S. Patient Survival report at bloodcell.transplant.hrsa.gov.

All diseases

Number of transplants by age reported from January 1, 2021 to December 31st, 2022 (includes marrow, PBSC and cord blood)

Treatments may be similar for diseases within a group. It might be helpful to look at centers that have done transplants for a specific disease and centers that have done transplants for any corresponding broad disease categories.